Athletic Integrative Medicine
Promising a Safe Future for Regenerative Medicine

The cascading initiatives of complementary and integrative medicine in biologics, wound care, and human cellular tissue-based products (HCT/P) are culminating in thousands of new scientific publications and a surge in breakthrough discoveries. Despite the ever-growing community of physicians and researchers eager to share information on this growing field, the FDA has still not granted pre-market approval to many stem cell-based HCT/P products. Without recognized regulations and approved clinical data backing innovative products, manufacturers, distribution networks, and Physicians are struggling to find a robust and legal avenue to effectively market HCT/P therapies.

At the forefront of a movement toward reliable marketing, powered by data-driven outcomes and compliant innovation, is Athletic Integrative Medicine (AIM), a medical consulting and supply chain network specializing in regenerative biologics and emerging medical devices. It provides training, education, and legally-vetted marketing support to help its partners consistently maintain regulatory compliance. The company was established based on years of engagement and support from some of the most observant industry specialists, who envisioned the best patient outcomes powered by long-term market presence. Through this vision, AIM delivers to its partners all the necessary support to ensure effective and repeatable results for their patient population which translates to lasting success for these businesses. Today, AIM functions on a patient-first belief system that places compliance on top. The company ensures that its workforce aligns with the same ideologies across the customer service and legal compliance facets of implementing best-in-class technology.

Unlike larger healthcare distribution chains that simultaneously support numerous clients, AIM’s goal is to target a smaller number of businesses and deliver unmatched intuitiveness during collaborations. This allows AIM to understand the inner workings of a client office and customize its offerings to address their prevalent needs. It also trains clients in developing a comprehensive and legal dialogue to present their products to respective communities and increase their financial and clinical footprint through compliant outreach strategies. In essence, AIM comprehensively explains the availability and compatibility of regulatory protocols to ensure the delivery of desired patient outcomes.

“We provide consultations for medicine, biologics, and medical devices to our partners through a holistic approach by determining the industry protocols best suited to satisfy all client requirements,” states Doug Rainey, owner and founder of Athletic Integrative Medicine.

AIM caters to its clients on multiple fronts—integrative HCT/P (stem cell) products, regenerative wound care, medical aesthetics, and dermatology. AIM is founded and focused on the advancement of Regenerative Medicine as a whole, and as such the company drives a large portion of its business through full scale introduction and implementation of stem cell-based regenerative medicine products in the private commercial space. Whether AIM is providing flowable, cellular/acellular HCT/Ps to an Integrative Pain Management facility or dehydrated amniotic chronic wound allografts to a Vascular Surgeon, its experience is robust enough to know that product supply is only the beginning of the journey to a fruitful partnership. AIM has the ability to help transform a historically insurance-based medical office into a fully diversified cashpay clinic, and can simultaneously teach a functional medicine clinic the intricacies of proper insurance billing/coding through their network of professional support.

In one of the most notable testimonies to its services, a Physician Partner of AIM was approached by a 65-year-old patient who had suffered a stroke five years prior. Her right eye was fully closed, her right arm and hand were fully contracted, she dragged her right leg, and she had a misaligned jaw, which significantly impacted her quality of life. AIM provided a single intravenous application of stem cell therapy. Two days later, her tremors were reduced by 50 percent and her right eye had opened completely. Three weeks later, the patient reported that she was regaining dexterity in her right arm and undertaking pegboard activities. She even began singing—an activity she had not performed in years, leading to a very emotional reaction from her family. This engagement perfectly illustrates AIM’s role in transforming a patient’s life for the better.

AIM routinely tackles advanced biologics technologies and adapts to offer the most progressive regenerative therapies to the market. Going forward, AIM plans to continue providing unmatched clinical competency, marketing, backend support, and quality legal compliance to its partners, boosting their ability to deliver transformative patient outcomes.